Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
A biomarker to predict future response to ixekizumab therapy was investigated in a single phase 2 study and has not been replicated. This experiment evaluated the correlation between baseline mRNA expression of TRGV and clinical response to ixekizumab in patients with chronic moderate-to-severe plaque psoriasis. 1
There are no current commercial assays that test for TRGV levels, and there are no standards that would define high levels of TRGV.1
Phase 3 clinical trials
Lilly has not tested biomarkers in phase 3 studies.
1. Krueger JG., Suarez-Farinas M, Beselin A, et al. Baseline expression of T cell receptor gamma-V gene family is associated with high levels of response to ixekizumab treatment in psoriasis. J Invest Dermatol 2015; 135: S32-S32. http://www.jidonline.org/article/S0022-202X(15)60202-0/pdf
Glossary
Lilly = Eli Lilly and Company
TRGV = T cell receptor gamma-V
Datum fӧr senaste ӧversyn 2019 M03 04